One-Day Quadruple Therapy Compared With 7-Day Triple Therapy for *Helicobacter pylori* Infection

Luis F. Lara, MD; Gerardo Cisneros, MD; Michael Gurney, MD; Michael Van Ness, MD; David Jarjoura, PhD; Betty Moauro, RN; Ann Polen, MEd; Gregory Rutecki, MD; Frederick Whittier, MD

**Background:** Eradication of *Helicobacter pylori* infection has had an impact on the treatment and recurrence rates of peptic ulcer disease and malignancies such as mucosa-associated lymphoid tissue lymphoma. Treatment options are cumbersome, expensive, and associated with side effects.

**Methods:** Randomized, prospective, open-labeled equivalence trial with a parallel-group design to compare eradication rates of *H pylori* with a 1-day, 4-drug regimen with a 7-day, 3-drug regimen. A total of 160 patients with dyspepsia and a Glasgow Dyspepsia Severity Score of at least 3 had a urea breath test labeled with carbon 14. Patients who tested positive were randomized to 1 of the 2 study groups. The study was designed to test the therapeutic equivalence of 1-day and 7-day regimens based on the percentage of *H pylori* eradication in each group at 5 weeks.

**Results:** The 1-day treatment group (n=80) had a slightly higher eradication percentage (95%) than the 7-day group (90%). The possible inferiority of the 1-day treatment relative to the 7-day treatment, a 15% difference in the number of patients whose infection was not eradicated at 5 weeks, was rejected (P<.001; 90% confidence interval, 2.7%-11%). Both groups demonstrated a mean decrease of 7.5 points in the Glasgow Dyspepsia Severity Score. The 2 groups showed no significant differences in side effects. Patients whose treatment failed (4 in the 1-day treatment group and 7 in the 7-day treatment group) were retreated for 10 days. One patient from the 7-day treatment group still tested positive after the second treatment.

**Conclusions:** The 1-day treatment proved to be statistically similar to the 7-day treatment for the eradication of *H pylori* in patients with dyspepsia and a positive urea breath test. Further evaluation will be necessary to determine whether the 1-day regimen is adequate for patients with peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, or gastric adenocarcinoma.

Arch Intern Med. 2003;163:2079-2084

Since Marshall and Warren first described *Helicobacter pylori* in 1983, the observation that linked infection with this organism to gastritis and peptic ulcer disease has been extended. Despite recent reports of a decline in the prevalence of *H pylori* among patients with active ulcers, the association remains consistent.

The eradication of *H pylori* infection in patients with peptic ulcer disease has been proven to be a cost-effective method to reduce ulcer recurrence rates and complications. *Helicobacter pylori* is a well-described risk factor for the development of gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma, which have high rates of remission when treated in their early stages. It is also believed that treatment might prevent the progression of gastric metaplasia. Treatment of *H pylori* infection is currently accepted for patients with dyspepsia, even though dyspepsia and gastroesophageal reflux symptoms may worsen after *H pylori* eradication.

Multiple therapies to eradicate *H pylori* are available, and combinations have higher eradication rates than single-antibiotic regimens. Earlier therapies lasted up to 21 days and included up to 4 different medications. These therapies produced undesirable side effects such as nausea, vomiting, and diarrhea, which negatively affected compliance and, therefore, eradication rates.

Shorter, triple-drug regimens have been developed, consisting of a proton-pump inhibitor (PPI), clarithromycin, and another antibiotic—typically, amoxicillin or metronidazole—given twice a day (bid). Fourteen-day, bid triple-drug regimens yield eradication rates of more than...
less than 3.43 includes 8 items, with a maximum score of 20. Resolution of dyspepsia symptoms. This simple and rapidly administered test is administered to patients after they finished the prescribed therapy, and patient compliance was assessed by direct pill counts. The GDSS was administered after therapy as well. The trial was designed to test the therapeutic equivalence of a single-day treatment for H pylori infection demonstrated eradication rates greater than 72%. A randomized study comparing a 7-day triple therapy with a 1-day quadruple therapy was stopped when interim analysis showed very poor (20%) eradication rates for the 1-day group. 38 One-day therapeutic protocols, to our knowledge, have not been published in the United States. This equivalence trial compares eradication rates of a 1-day, 4-drug treatment with a 7-day, 3-drug treatment.

**METHODS**

**STUDY DESIGN**

This study is a randomized, prospective, open-label equivalence trial with a parallel-group design. Patients with dyspepsia and H pylori infection were included if they had a positive urea breath test labeled with carbon 14 (14C-UBT) and a Glasgow Dyspepsia Severity Score (GDSS) above 2. They were identified during scheduled visits to the ambulatory internal medicine clinics of the Northeastern Ohio Universities College of Medicine Affiliated Hospitals at Canton (the Aultman Hospital and the Mercy Medical Center).

**PATIENT SELECTION**

Patients with dyspepsia symptoms were assessed with the GDSS, a validated tool for evaluating the severity and frequency of symptoms. This simple and rapidly administered test includes 8 items, with a maximum score of 20. Resolution of dyspepsia is considered to be successful if the GDSS decreases to less than 3.

Patients were selected for a 14C-UBT only if their GDSS scores were 3 or higher. This test is an inexpensive and reliable alternative to endoscopy plus biopsy and histological examination or to the CLO test. 39 We used the microCOUNT Model 9605 Liquid Scintillation Counter (Tri-Med Specialties Inc, Draper, Utah) for urea breath testing. Patients received an oral capsule of urea in which 14C was replaced with radioactive 13C (the exposure is less than for a chest radiography). The urea split by H pylori urease produces carbon dioxide and ammonia; the isotopes diffuse into the bloodstream and are expelled by the lungs as carbon dioxide C 14 which is qualitatively measurable. Measurements were taken 20 minutes after ingestion of the urea capsule to prevent a false-positive result due to oral flora. The patients were not taking antibiotics, bismuth, or acid-suppressive medications to avoid a false-negative result.

Inclusion criteria were dyspepsia, a GDSS of 3 or higher, and a positive 14C-UBT. Exclusion criteria included previous treatment of H pylori infection, pregnancy, age less than 18 years, personal or family history of gastrointestinal malignancy, antibiotic therapy in the previous 6 weeks, previous gastric surgery, hepatic insufficiency (Child-Pugh class B or C), creatinine clearance of less than 20 mL/min, use of a PPI in the previous 2 weeks, allergy to any of the medications included in the protocol, and danger signs or symptoms such as dysphagia, weight loss, or bleeding that would indicate a need for endoscopy.

**TREATMENT GROUPS**

Eligible patients signed an informed consent form approved by the institutional review board of both hospitals and were randomized to 1 of 2 study groups. The treatment group received a 1-day regimen consisting of two 262-mg tablets of bismuth subsalicylate 4 times daily (qid); of one 500-mg tablet of metronidazole qid; of 2 g of amoxicillin suspension qid; and of two 30-mg tablets of lansoprazole once daily. The control group received a 7-day regimen that included one 500-mg tablet of clarithromycin bid; two 500-mg tablets of amoxicillin bid; and one 30-mg tablet of lansoprazole bid.

All patients were asked to avoid antibiotics and acid-suppression medications until a second 14C-UBT was performed 5 weeks after termination of therapy. Eradication of infection with H pylori was defined as a negative 14C-UBT 5 weeks after treatment. Patients in either group who had a positive second 14C-UBT were treated for 10 days with 500 mg of clarithromycin bid, 1 g of amoxicillin bid, 30 mg of lansoprazole bid, and 524 mg of bismuth subsalicylate qid. The 14C-UBT was repeated 5 weeks later. Side effects were identified using a questionnaire administered to patients after they finished the prescribed therapy, and patient compliance was assessed by direct pill counts. The GDSS was administered after therapy as well.

**STATISTICAL METHODS**

The trial was designed to test the therapeutic equivalence of 1-day and 7-day treatments based on the proportion of patients in each group whose H pylori infection was eradicated at 5 weeks. 39 An equivalence trial was appropriate because eradication with the 7-day treatment is reported to be approximately 90%, which might be difficult to improve on. 40,41 The sample size of 80 patients per group provided 90% power to reject the inferiority of the 1-day treatment at α = .05. It was assumed in the sample size calculation that the 7-day treatment would eradicate H pylori in 90% of patients. A difference of 15% in the number of patients with eradication in the 1-day group at the 5-week follow-up visit was considered the threshold of inferiority. A 1-sided confidence interval (CI) for the difference between the groups is the standard for equivalence trials such as this one because it protects the nominal α level. 32 Other analyses compared GDSS scores at 5 weeks, adjusted for baseline differences between groups, and compared reported side effects with CIs.

**RESULTS**

Subjects with a GDSS score of at least 3 and a positive 14C-UBT were recruited from August 1998 to December 2000. Of the 160 patients enrolled, 10 patients (3 from the 1-day and 7 from the 7-day group) did not return for the 5-week 14C-UBT. Table 1 provides a comparison of the 1-day and 7-day groups at baseline for GDSS, sex, and age. The 95% CIs indicate no significant baseline differences between the groups regarding GDSS, sex, and age. The 95% CIs include zero. Patients were slightly older in the 7-day group than in the 1-day group.

---

Note: The text above is a natural representation of the content, formatted for readability. It includes some corrections and additions for clarity.
ERADICATION PERCENTAGE

The 1-day treatment had a higher eradication percentage (95%) than the 7-day treatment (90%). According to our primary hypothesis test, the inferiority (a difference in rates ≥15%) of the 1-day treatment relative to the 7-day treatment was rejected at P<.001. Table 2 includes percentages of patients in each group whose 14C-UBT was negative at the 5-week evaluation. Table 2 also provides the lower limit of the 90% CI on the difference between the 1-day and the 7-day groups. The −2.7% value is at the border of remaining consistent with these data, which allows the conclusion that, for a population similar to the one included in this study, the deficit in percentage of eradication in a 1-day treatment group, compared with a 7-day treatment group, would not be more than 2.7%. It is even possible that the 1-day treatment is superior to the 7-day treatment. (The upper limit of the CI on the difference indicates that the 1-day treatment is not more than 11% superior to the 7-day treatment; however, this study was not designed to test the superiority of the 1-day treatment, and it should be noted that it was not significantly superior.) Table 1 shows that the 7-day group was older, but that fewer patients in that group had a history of smoking. After adjusting for age and differences between the groups in sex, alcohol use, race, and history of smoking using a logistic regression model, it was found that the baseline differences had minimal impact on the results. The adjusted difference was 4% and the unadjusted difference was 4.5% in favor of the 1-day treatment. Table 2 also provides the change from baseline in GDSS scores. Both groups demonstrated a mean decrease of 7.5 percentage points.

SECONDARY ANALYSIS

None of the patients in either group expressed intolerance to their assigned treatment. None were grossly noncompliant with their treatment (ie, no 1-day patient crossed to the 7-day group or vice versa). Although intention-to-treat analyses are commonly used in superiority trials, they are inappropriate in equivalence trials because they bias toward equivalence.

TREATMENT FAILURES

Treatment was unsuccessful for 4 patients in the 1-day treatment group and 7 patients in the 7-day treatment group. Of the 4 patients in the 1-day treatment group who were subsequently treated with the 10-day course, 1 did not return for the second 5-week 14C-UBT and the other 3 tested negative. Of the 7 patients in the 7-day treatment group, 1 had a positive result at the second follow-up 14C-UBT but refused endoscopic evaluation or further therapy.

### Table 1. Patient Characteristics at Baseline

<table>
<thead>
<tr>
<th>Variable</th>
<th>Treatment Group</th>
<th>95% CI for Difference Between the Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7-Day (n = 80)</td>
<td>1-Day (n = 80)</td>
</tr>
<tr>
<td>GDSS, mean (SD)</td>
<td>10 (3.3)</td>
<td>11 (3.4)</td>
</tr>
<tr>
<td>Sex, % women</td>
<td>59</td>
<td>55</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>53 (16)</td>
<td>46 (12)</td>
</tr>
<tr>
<td>History of smoking, %</td>
<td>12</td>
<td>34</td>
</tr>
<tr>
<td>Current alcohol consumption, %</td>
<td>52</td>
<td>52</td>
</tr>
<tr>
<td>African American, %</td>
<td>14</td>
<td>16</td>
</tr>
</tbody>
</table>

**Note:** CIs on the difference did not reveal any significant differences between the 2 groups. Because side effects could have been associated with greater noncompliance in the 7-day treatment group, a search was done for a negative association between fewer side effects and eradication, and none was found (odds ratio, 0.9; P = .9). Adjusting for side effects had no impact on the positive difference observed between 1-day and 7-day eradication percentages.

### Table 2. Eradication Percentages and GDSS Scores by Group at 5-Week Follow-up

<table>
<thead>
<tr>
<th>Variable</th>
<th>Treatment Group</th>
<th>1-Sided CI for Difference Between the Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7-Day (n = 73)</td>
<td>1-Day (n = 77)</td>
</tr>
<tr>
<td>Eradication, % (No.)</td>
<td>90 (66)</td>
<td>95 (73)</td>
</tr>
<tr>
<td>GDSS change from baseline, mean (SD)*</td>
<td>−7.5 (3.2)</td>
<td>−7.5 (3.5)</td>
</tr>
</tbody>
</table>

*The 5-week Glasgow Dyspepsia Severity Score (GDSS) means were 2.8 for the 7-day and 3.8 for the 1-day treatment group. Note in Table 1 that the mean for the 1-day group is 1.0 higher than for the 7-day group at baseline.

### Table 3. Percentage of Patients Reporting Side Effects by Group

<table>
<thead>
<tr>
<th>Side Effect</th>
<th>Treatment Group</th>
<th>95% CI for Difference Between the Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7-Day (n = 73)</td>
<td>1-Day (n = 77)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>Stool discoloration</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Nausea</td>
<td>26</td>
<td>14</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Metallic taste</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Headache</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Yeast infection</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Constipation</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

**Abbreviation:** CI, confidence interval.
To successfully eradicate *H pylori* infection, the use of combination regimens known to have an acceptably high cure rate is vital. Therapies to treat *H pylori* infection should produce eradication rates of at least 90%,\textsuperscript{26,30,31,33,33} Furthermore, when developing a treatment plan, compliance, adverse reactions, and cost are additional factors that need to be considered.

Current regimens use a combination of 2 antibiotics with 1 or 2 nonantibiotic adjunctive agents. Fourteen-day, bid triple therapy regimens almost uniformly produce eradication rates higher than 90%, but these regimens are expensive and adverse effects such as nausea and diarrhea are common.\textsuperscript{33,33-65} Lind et al\textsuperscript{35} demonstrated in the MACH (Metronidazole Amoxicillin Clarithromycin Helicobacter pylori) I study that a 7-day bid triple-therapy regimen achieves similar and acceptable results. This led to the Maastricht Consensus Report and the Canadian *Helicobacter pylori* Consensus Conference recommending a triple therapy consisting of a PPI, amoxicillin, plus 1 of 2 other antibiotics (clarithromycin or metronidazole) as first-line therapy to treat *H pylori* infection.\textsuperscript{38,32} This regimen achieves an eradication rate higher than 80% with intention-to-treat analysis and higher than 90% per protocol, at a lower cost.\textsuperscript{30,35,55-65}

Quadruple therapies lasting 7 to 14 days that include a bismuth compound produce excellent eradication rates, but these regimens are relegated to second-line therapy because their complex dosing schedule and less tolerable side-effect profiles decrease compliance.\textsuperscript{26,66-68}

Shorter therapies achieving eradication rates similar to those of 7- or 14-day treatments would be desirable to ensure patient compliance. Short therapies could only be recommended if they produced an acceptable eradication rate, and if patients subsequently tested negative for *H pylori*.\textsuperscript{35} The short therapies that have produced acceptable cure rates (up to 96%) have combined a bismuth salt, a PPI, and 2 antibiotics. Some of the regimens included a PPI for a longer time (up to 14 days) than the antibiotics.\textsuperscript{33,35-38,54,66-67} Eradication is confirmed on long-term follow-up when short therapies are used.\textsuperscript{54}

Three European studies have addressed eradication using a single-day quadruple drug regimen. Tuucci et al\textsuperscript{31} first achieved an eradication rate of 72%, and Takatsu et al\textsuperscript{32} then reported eradication in 76.5% of patients with duodenal ulcer and 83% of patients with dyspepsia. The randomized study by Wermelle et al,\textsuperscript{39} published after the initiation of our study, showed very poor eradication rates for their 1-day therapy group.

Amoxicillin is an antibiotic to which *H pylori* is sensitive in vitro, but has little impact when used in vivo as monotherapy at usual doses. However, when this antibiotic is used in high doses, only a short gastric contact time is needed to kill *H pylori*. Metronidazole is actively secreted into gastric juice and saliva, and its activity is independent of pH. Resistance to metronidazole can be avoided when it is given in combination with bismuth salicylate, a topical antimicrobial agent that directly disrupts the bacterial cell wall. Finally, PPIs increase intragastric pH, may enhance the effectiveness of the local immune response, reduce the mucosal washout of antibiotics, and may have bactericidal activity.\textsuperscript{31,12,21,30,31,55,63,65,72,76}

The 14C-UBT is accepted as the noninvasive gold standard to diagnose *H pylori* infection, with reported sensitivity of more than 90% and specificity of more than 95%.\textsuperscript{26,30,47-49} Shorter therapies have been criticized because of the possibility of suppression without eradication of *H pylori*, leading to false-negative 14C-UBT or histological findings, and there are concerns that sensitivity could drop to 90% in the follow-up 14C-UBT. Even though it has been demonstrated that 14 days off PPI will eliminate the false-negative rate, we elected to wait 5 weeks to repeat the 14C-UBT.\textsuperscript{4,66,77,78} Noninvasive tests for *H pylori*, including serum antibody tests and carbon 14-labeled breath tests, are reportedly as accurate in diagnosing the presence of *H pylori* as invasive tests.\textsuperscript{28,40,79,80} The 14C-UBT is an ideal test as it is accurate, cost-effective, and 3 to 4 times less expensive than invasive testing.\textsuperscript{40,44,79,81}

An important consideration is the significantly lower cost of the 1-day regimen ($32), vs the 7-day regimen of the control group ($182). Eradication was achieved in 9 (82%) of 11 patients for whom initial therapy was not successful (subsequent therapy was not successful in 1 patient, and 1 patient did not have the follow-up 14C-UBT). Quadruple therapy, typically including bismuth, is very efficacious to treat patients for whom triple therapy has failed. Acceptable eradication rates have been achieved in as few as 7 days of quadruple therapy.\textsuperscript{80-84}

The GDSS was used to evaluate the severity of symptoms before and after therapy. There was a substantial decline in severity in both groups relative to baseline, but the mean scores were still above normal. This is consistent with other studies demonstrating the modest benefit of *H pylori* eradication in dyspepsia.\textsuperscript{26,27}

Quadruple therapies lasting 7 to 14 days that include a bismuth compound produce excellent eradication rates, but these regimens are relegated to second-line therapy because their complex dosing schedule and less tolerable side-effect profiles decrease compliance.\textsuperscript{26,66-68}

The results observed in the present study demonstrate that eradication of *H pylori* infection can be achieved with a short-treatment regimen at a mean±SD success rate of 95%±2.5%, a rate similar to those of longer combination therapies. The approach to *H pylori* eradication reported in this study is cost-effective, promotes patient compliance, and could simplify the role of primary care physicians in the treatment of *H pylori* infection. We advocate posttreatment testing in patients in whom eradication confirmation is desirable, eg, patients with persistent symptoms or a history of peptic ulcer disease.

Accepted for publication November 21, 2002.

This study was funded in part by a grant from the Aultman Health Foundation, Canton, Ohio. Some medications were provided by TAP Pharmaceutical Products Inc, Lake Forest, Ill. Other financial support was provided by the Canton Medical Education Foundation.

This study was presented in abstract form at the annual session of the American College of Physicians National Meeting: March 29, 2001; Atlanta, Ga.

Corresponding author and reprints: Frederick Whittier, MD, Affiliated Hospitals at Canton, 1320 Mercy Dr NW, Canton, OH 44708 (e-mail: nancy.castro@csauh.com).


72. Catalano F, Catanzaro R, Branciforte G, et al. Five-day triple therapy in *Helico-


81. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection. *Gas-

